Work

Resistentie en HIV infectie : resistentie ontwikkeling tegenover twee nieuwe antiretrovirale middelen en natuurlijke variabiliteit van de cellulaire cofactor LEDGF/p75

Year: 2007
Type: dissertation
Abstract: Since the first cases of AIDS were reported in 1981 and the discovery of its etiologic agent, the human immunodeficiency virus (HIV), in 1983, the virus has killed more than 2.9 million people worldwide. About 4.3 million were newly infected in 2006. At the end of 2006 approximately 39.5 million people are living with the disease. Conventional antiretroviral medications consist of 4 different classes of drugs: 1) nucleoside reverse transcriptase (RT) inhibitors, 2) non-nucleoside reverse transcriptase inhibitors, 3) protease inhibitors and 4) one fusion inhibitor. Combinations of these agents provide potent suppression of HIV-1 RNA loads and have dramatically improved clinical outcomes for many patients. Despite the potency of this antiretroviral therapy, the emergence of HIV strains resistant to the presently available anti-HIV drugs is an important factor in therapy failure. Therefore it is extremely important that new compounds are developed that target other steps of the replication cycle of HIV. Whereas the virus can become resistant towards the administered antiretroviral drugs, another kind of resistance, called innate immunity, also occurs. Differences in genome sequence, due to a selective pressure, can render an individual resistant against the development of certain diseases and/or virus infections. Natural resistance to HIV-1 infection, while rare, does exist. Individuals homozygous for a 32 bp deletion in the gene coding for the CCR5 co‑receptor of HIV-1 are resistant to infection with an HIV-1 CCR5 strain. At the onset of my PhD, SPL2923, a polyanionic dendrimer, had been identified in our laboratory as an entry inhibitor of various HIV-1 and HIV-2 strains, including clinical HIV isolates and SIV(mac251). At that time, reverse transcription and integration, however, could not be excluded as possible target steps in the HIV replication cycle of SPL2923. Next to this entry inhibitor, the pyranodipyrimidine V-165 had also been identified in our laboratory as an integrase inhibitor. Mechanism of action studies revealed that V-165 interferes with DNA‑IN complex formation. As such V-165 is the prototype of the integrase binding inhibitors (INBI’s). At the same time, LEDGF/p75 was identified in our laboratory as an important co‑factor of HIV-1 integration and replication. However, little was known about the natural variability of the gene coding for LEDGF/p75. My doctoral work focused on the following objectives: 1) Specify the antiviral target and the molecular mode of action of the HIV-1 entry inhibitor SPL2923, 2) Study the effect of mutations found in the integrase (IN) gene of a HIV-1 strain resistant towards the integrase binding inhibitor V-165, on the enzymatic activity and the susceptibility against the inhibitory effect of several anti-HIV drugs, including V‑165, 3) Evaluate if there is an innate immunity associated with mutations in LEDGF/p75 that protects individuals against infection with HIV‑1. The study of HIV-1 resistance development against inhibitors of viral entry, SPL2923 or integration, V-165, included the selection of HIV-1 in the presence of increasing concentrations of inhibitor and the genotypic and phenotypic analysis of this selected strain. Chimeric Virus Technology (CVT) was used for the recombination of the HIV-1 env genes gp120, gp41 and gp160, and the integrase gene. Resistance selection against the polysulfonic dendrimer SPL2923 resulted in mutations in both gp120 and gp41 of the selected strain. No mutations were found in RT or IN. Phenotypic analysis revealed that the mutations in env alone were not sufficient to explain the resistance profile of the selected resistant strain. Sequencing of the gene coding for p17, the matrix protein, revealed the association of mutations in the matrix protein with resistance to SPL2923. CVT was established that enabled the recombination of both p17, alone or in combination with gp160, into a wild type background. By gp160‑, p17- and p17/gp160-recombination experiments we proved that the mutations in both the env and gag genes contribute to the resistance of the selected strain and need to be present simultaneously to reproduce the resistance phenotype towards SPL2923. Genotypic analysis of PDP-resistant HIV-1 strains revealed mutations in the IN gene in an early stage, while mutations in RT and env appeared at a later stage. Recombinant mutant integrase was purified. In an oligonucleotide-based assay, a slight reduction in over-all enzymatic activity was observed for all the mutant integrase enzymes, except for S230N, which showed WT activity. An IN/DNA interaction assay demonstrated that all the mutant integrases showed a decreased affinity for DNA. Additionally, the mutant enzymes showed a slight resistance to V-165 in this IN/DNA interaction assay. This study revealed that the observed IN mutations interfere with the enzymatic activity and the DNA binding capacity of HIV-1 IN enzymes and that the mutations are responsible for a low-level resistance against PDP. Additional experiments were performed to further analyze the resistance profile of the selected strains. By means of IN-, RT- or gp160‑CVT, a quantitative viral adsorption assay and Quantitative PCR analysis of the three HIV DNA species after HIV-1 infection and HIV‑1 vector transduction, we conclude that V‑165 exploits a multi‑modal mechanism of action. However, we still propose integrase binding inhibition as a genuine antiviral target and V-165 as the INBI prototype. To investigate whether there is an innate immunity due to mutations in LEDGF/p75, DNA sequencing analysis of three different groups was performed: 1) a HIV seronegative African control group, 2) a HIV exposed seronegative African group of female sex workers and 3) a HIV seropositive African group of female sex workers. Next to mutations in introns, that did not result in an alternatively spliced protein, one mutation in an exon was found. As a consequence, the Q472L mutation was present in LEDGF/p75. This mutation was located outside the integrase binding domain in LEDGF/p75. The Q472L mutation was found in 1 out of the 19 samples of the control group, in 3 out of the 20 samples of the seronegative African group and in 1 out of the 20 samples of the seropositive African group. Statistical analysis revealed that the prevalence of the Q472L mutation in the HIV exposed seronegative group and the seropositive group was not statistically different (p = 0.61). Recombinant mutant LEDGF/p75 did not show a difference in binding capacity to IN compared to WT. In a next step, HIV-1 replication was analyzed in LEDGF/p75 knockdown MT-4 cell lines. A 50% reduction in viral replication was observed. Back complementation of WT or mutant(Q472L) LEDGF/p75 restored the viral replication, however no difference in replication was observed in the cell lines back complemented with mutant(Q472L) LEDGF/p75 compared to those back complemented with WT LEDGF/p75. Taken together, these results suggest that the presence of the Q472L mutation in LEDGF/p75 has no effect on the role of LEDGF/p75 in viral replication and does not render a person resistant to HIV infection.
Source: Lirias
Institution: KU Leuven
Language: English
Subfield: Virology
Open Access status: green
OpenAlex ID: W7024415215
Cites: 110
Cited by:
Related to: 10